These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16523360)

  • 41. Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity.
    Pagnanelli G; Bono R; Pizzichetta MA; Talamini R; Ascierto PA; Testori A; Stanganelli I;
    Anticancer Res; 2007; 27(4C):2939-44. PubMed ID: 17695474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.
    Aloia TA; Gershenwald JE; Andtbacka RH; Johnson MM; Schacherer CW; Ng CS; Cormier JN; Lee JE; Ross MI; Mansfield PF
    J Clin Oncol; 2006 Jun; 24(18):2858-65. PubMed ID: 16782925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The prognostic importance of sentinel lymph node biopsy in thin melanoma.
    Ranieri JM; Wagner JD; Wenck S; Johnson CS; Coleman JJ
    Ann Surg Oncol; 2006 Jul; 13(7):927-32. PubMed ID: 16788753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
    Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
    Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes.
    Satzger I; Völker B; Meier A; Kapp A; Gutzmer R
    Ann Surg Oncol; 2008 Jun; 15(6):1723-32. PubMed ID: 18389323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma.
    Pearlman NW; McCarter MD; Frank M; Hurtubis C; Merkow RP; Franklin WA; Gonzalez R; Lewis K; Roaten JB; Robinson WA
    Am J Surg; 2006 Dec; 192(6):878-81. PubMed ID: 17161112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.
    Huo L; Sneige N; Hunt KK; Albarracin CT; Lopez A; Resetkova E
    Cancer; 2006 Oct; 107(8):1760-8. PubMed ID: 16977650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of nonsentinel lymph node metastasis in malignant melanoma.
    Cadili A; Smylie M; Danyluk J; Dabbs K
    J Surg Res; 2009 Jun; 154(2):324-9. PubMed ID: 19101696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis.
    Chagpar RB; Ross MI; Reintgen DS; Edwards MJ; Scoggins CR; Martin RC; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; McMasters KM
    J Surg Res; 2007 Nov; 143(1):164-8. PubMed ID: 17950088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group.
    Cook MG; Spatz A; Bröcker EB; Ruiter DJ
    J Pathol; 2002 Jun; 197(2):188-93. PubMed ID: 12015742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa.
    Ho VH; Ross MI; Prieto VG; Khaleeq A; Kim S; Esmaeli B
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):820-6. PubMed ID: 17709624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.
    Bartlett EK; Gimotty PA; Sinnamon AJ; Wachtel H; Roses RE; Schuchter L; Xu X; Elder DE; Ming M; Elenitsas R; Guerry D; Kelz RR; Czerniecki BJ; Fraker DL; Karakousis GC
    Ann Surg Oncol; 2014 Feb; 21(2):643-9. PubMed ID: 24121883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular staging for patients with malignant melanoma.
    Shivers S; Jakub J; Pendas S; Reintgen D
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center.
    Sassen S; Shaw HM; Colman MH; Scolyer RA; Thompson JF
    Ann Surg Oncol; 2008 Feb; 15(2):630-7. PubMed ID: 18080717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients.
    Leong SP; Accortt NA; Essner R; Ross M; Gershenwald JE; Pockaj B; Hoekstra HJ; Garberoglio C; White RL; Chu D; Biel M; Charney K; Wanebo H; Avisar E; Vetto J; Soong SJ;
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):370-3. PubMed ID: 16618904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of ThinPrep cytology in the investigation of SLN status in patients with cutaneous melanoma.
    Papadopoulos O; Konofaos P; Georgoulakis J; Chrisostomidis C; Tsantoulas Z; Kostopoulos E; Stratigos A; Karipidis D; Karakitsos P
    Surg Oncol; 2007 Aug; 16(2):121-9. PubMed ID: 17703937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.
    Bartlett EK; Peters MG; Blair A; Etherington MS; Elder DE; Xu XG; Guerry D; Ming ME; Fraker DL; Czerniecki BJ; Gimotty PA; Karakousis GC
    Ann Surg Oncol; 2016 Jan; 23(1):250-6. PubMed ID: 26215202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
    Wong SL; Morton DL; Thompson JF; Gershenwald JE; Leong SP; Reintgen DS; Gutman H; Sabel MS; Carlson GW; McMasters KM; Tyler DS; Goydos JS; Eggermont AM; Nieweg OE; Cosimi AB; Riker AI; G Coit D
    Ann Surg Oncol; 2006 Jun; 13(6):809-16. PubMed ID: 16604476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.